van Oosten M, van de Bilt E, van Berkel T J, Kuiper J
Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, University of Leiden, 2300 RA Leiden, The Netherlands.
Infect Immun. 1998 Nov;66(11):5107-12. doi: 10.1128/IAI.66.11.5107-5112.1998.
Lipopolysaccharide (LPS) is cleared from the blood mainly by the liver. The Kupffer cells are primarily responsible for this clearance; liver endothelial and parenchymal cells contribute to a lesser extent. Although several binding sites have been described, only CD14 is known to be involved in LPS signalling. Among the other LPS binding sites that have been identified are scavenger receptors. Scavenger receptor class A (SR-A) types I and II are expressed in the liver on endothelial cells and Kupffer cells, and a 95-kDa receptor, identified as macrosialin, is expressed on Kupffer cells. In this study, we examined the role of scavenger receptors in the binding of LPS by the liver in vivo and in vitro. Fucoidin, a scavenger receptor ligand, significantly reduced the clearance of 125I-LPS from the serum and decreased the liver uptake of 125I-LPS about 40%. Within the liver, the in vivo binding of 125I-LPS to Kupffer and liver endothelial cells was decreased 72 and 71%, respectively, while the binding of 125I-LPS to liver parenchymal cells increased 34% upon fucoidin preinjection. Poly(I) inhibited the binding of 125I-LPS to Kupffer and endothelial cells in vitro 73 and 78%, respectively, while poly(A) had no effect. LPS inhibited the binding of acetylated low-density lipoprotein (acLDL) to Kupffer and liver endothelial cells 40 and 55%, respectively, and the binding of oxidized LDL (oxLDL) to Kupffer and liver endothelial cells 65 and 61%, respectively. oxLDL and acLDL did not significantly inhibit the binding of LPS to these cells. We conclude that on both endothelial cells and Kupffer cells, LPS binds mainly to scavenger receptors, but SR-A and macrosialin contribute to a limited extent to the binding of LPS.
脂多糖(LPS)主要通过肝脏从血液中清除。库普弗细胞对此清除过程起主要作用;肝内皮细胞和实质细胞的作用较小。尽管已描述了几个结合位点,但已知只有CD14参与LPS信号传导。已鉴定出的其他LPS结合位点中有清道夫受体。A类清道夫受体(SR-A)I型和II型在肝脏的内皮细胞和库普弗细胞中表达,一种被鉴定为巨唾液酸蛋白的95 kDa受体在库普弗细胞中表达。在本研究中,我们检测了清道夫受体在体内和体外肝脏对LPS结合中的作用。岩藻依聚糖是一种清道夫受体配体,它显著降低了血清中125I-LPS的清除率,并使肝脏对125I-LPS的摄取减少约40%。在肝脏内,岩藻依聚糖预注射后,125I-LPS与库普弗细胞和肝内皮细胞的体内结合分别减少了72%和71%,而125I-LPS与肝实质细胞的结合增加了34%。聚肌苷酸(Poly(I))在体外分别抑制125I-LPS与库普弗细胞和内皮细胞的结合73%和78%,而聚腺苷酸(Poly(A))则无作用。LPS分别抑制乙酰化低密度脂蛋白(acLDL)与库普弗细胞和肝内皮细胞的结合40%和55%,以及氧化低密度脂蛋白(oxLDL)与库普弗细胞和肝内皮细胞的结合65%和61%。oxLDL和acLDL并未显著抑制LPS与这些细胞的结合。我们得出结论,在内皮细胞和库普弗细胞上,LPS主要与清道夫受体结合,但SR-A和巨唾液酸蛋白对LPS结合的贡献有限。